翻訳と辞書 Words near each other ・ Prescribed scalar curvature problem ・ Prescribed senior official ・ Prescribed sum ・ Prescription ・ Prescription (sovereignty transfer) ・ Prescription Act 1832 ・ Prescription analytics ・ Prescription bottle ・ Prescription cascade ・ Prescription charges ・ Prescription costs ・ Prescription drug ・ Prescription Drug Marketing Act ・ Prescription drug prices in the United States ・ Prescription drug purchasing pool ・ Prescription Drug User Fee Act ・ Prescription for Death ・ Prescription for Murder ・ Prescription for Romance ・ Prescription monitoring program ・ Prescriptive analytics ・ Prescriptive authority for psychologists movement ・ Prescriptivism ・ Prescriptivity ・ Prescrire ・ Presdales School ・ Preseaca River ・ Preseault v. United States ・ Preseed ・ Preseglie Dictionary Lists mini英和辞書 mini和英辞書 Webster 1913 Latin-English FOLDOC Wikipedia English ウィキペディア

翻訳と辞書　辞書検索 [ 開発暫定版 ] スポンサード リンク Prescription Drug User Fee Act ： ウィキペディア英語版 Prescription Drug User Fee Act The ''Prescription Drug User Fee Act'' (PDUFA) was a law passed by the United States Congress in 1992 which allowed the Food and Drug Administration (FDA) to collect fees from drug manufacturers to fund the new drug approval process. The Act provided that the FDA was entitled to collect a substantial application fee from drug manufacturers at the time a New Drug Application (NDA) or Biologics License Application (BLA) was submitted, with those funds designated for use only in Center for Drug Evaluation and Research (CDER) or Center for Biologics Evaluation and Research (CBER) drug approval activities. In order to continue collecting such fees, the FDA is required to meet certain performance benchmarks, primarily related to the speed of certain activities within the NDA review process. ==History== The move towards imposing user fees to pay for the regulatory review of new medicines was the result of dissatisfaction among consumers, industry, and the FDA. All three groups felt that drug approvals were taking far too long. Pharmaceutical companies had to wait to begin to recoup the costs of research and development. The FDA estimated that a delay of one month in a review’s completion cost its sponsor $10 million. The FDA argued that it needed additional staff to end its back-log of drugs awaiting approval for market. The FDA had not received sufficient appropriations from Congress to hire them. For decades the FDA had asked for permission to implement user fees and the pharmaceutical industry generally opposed them, fearing that the funds would not be used to speed drug review. The 1992 law became possible when the FDA and industry agreed on setting target completion times for reviews and the promise these fees would supplement federal appropriations instead of replacing them. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Prescription Drug User Fee Act」の詳細全文を読む スポンサード リンク 翻訳と辞書 : 翻訳のためのインターネットリソース Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.